Get started

Abbottlabs

Abbott Labs Shakes Off Downtrend, Sets Sights on $142 milestoneIn December 2021, the stock price hit an all-time high near the 142 mark, after which it experienced a significant drop. Following this decline, the price found support around the 90 level and began to recover. Last week, the stock managed to break through the upper boundary of the descending parallel channel, setting the stage for additional upward momentum. An immediate resistance level is noted at the 122 level, and a substantial movement is expected if this level is surpassed.
NYSE:ABTLong
by NaranjCapital
Abbott Laboratories Shows Resilience with Strong Q1 Performance In the dynamic landscape of healthcare, Abbott Laboratories (NYSE: NYSE:ABT ) stands out with its robust first-quarter performance, showcasing resilience and adaptability amidst challenging conditions. Bolstered by a surge in medical device sales and buoyed by promising growth across multiple sectors, Abbott has exceeded expectations and raised its annual guidance, signaling confidence in its trajectory. Let's delve deeper into the factors driving Abbott's success and the implications for investors. 1. Medical Devices Lead the Charge: Abbott's ( NYSE:ABT ) first-quarter success story is largely attributed to the stellar performance of its Medical Devices segment, which witnessed a remarkable organic growth of 14.3%. The star performer within this segment was FreeStyle Libre, demonstrating a phenomenal 23.3% organic growth, underscoring the growing demand for innovative healthcare solutions. 2. Diversification Pays Off: Abbott's diversified portfolio, spanning Established Pharmaceuticals, Nutrition, and Diagnostics, was pivotal in driving overall growth. With double-digit organic growth in Established Pharmaceuticals and substantial gains in Nutrition and Diagnostics, Abbott has showcased its ability to capture opportunities across various healthcare segments. 3. Strategic Innovations: The approval of Abbott's Heart Valve Repair Device by the FDA marks a significant milestone, reinforcing the company's commitment to advancing medical technology. This breakthrough underscores Abbott's relentless pursuit of innovation to address critical healthcare needs, thereby positioning the company for sustained growth and market leadership. 4. Earnings Beat and Guidance Revision: Abbott's impressive adjusted diluted earnings per share of $0.98 not only surpassed analyst estimates but also instilled confidence in the company's financial performance. The upward revision of its fiscal year 2024 adjusted EPS guidance to $4.55-$4.70 reflects management's bullish outlook and underscores Abbott's strong growth prospects in the coming quarters. 5. Market Response and Outlook: Despite the premarket dip in NYSE:ABT shares, Abbott's robust performance and revised guidance signal a compelling investment opportunity. With a solid foundation, innovative pipeline, and optimistic outlook, Abbott is poised to navigate uncertainties and deliver sustainable value to shareholders in the long term.
NYSE:ABT
by DEXWireNews
Abbott Laboratories (ABT) Navigating Earnings Abbott Laboratories ( NYSE:ABT ) recently reported earnings that slightly missed expectations at the midpoint, causing a 3.3% dip in NYSE:ABT stock to $110.21. However, a closer look at the results reveals a more nuanced story. Despite the earnings guidance falling short by three pennies at $4.60 per share for the year, the health care giant remains resilient, projecting a robust 8% to 10% organic sales growth. Investors should pay attention as NYSE:ABT stock forms a saucer base with a potential buy point at $115.83. Strong Growth in Medical Devices: One of the key drivers behind Abbott's solid performance was the outstanding growth in its medical devices segment. Sales in this category surged 15.4% organically to $4.44 billion. Notably, the diabetes division played a significant role, with revenues reaching $1.55 billion, marking a substantial 20.7% increase. The star performer in this space was Abbott's body-worn glucose monitor, FreeStyle Libre, which contributed $1.4 billion in sales, up by an impressive 23.8% on an organic basis. Electrophysiology Segment Shines: Another highlight for Abbott ( NYSE:ABT ) was the electrophysiology segment, where revenue grew 15.9% organically to nearly $2.2 billion. This growth is particularly noteworthy considering the challenges posed by a new technology called pulsed field ablation (PFA), which is emerging in the electrophysiology testing space. Analysts believe that Abbott's robust performance in this segment allays fears of losing market share to PFA, underscoring the company's adaptability and resilience. Rapid Diagnostics Faces Headwinds: While Abbott ( NYSE:ABT ) celebrated success in medical devices and electrophysiology, the rapid diagnostics segment faced headwinds. Excluding Covid tests, sales declined by 13.7% to $862 million. The decline was attributed to a later-than-expected flu season, with cases spiking in January. Despite this setback, core lab sales managed to climb 9.7% to $1.37 billion, showcasing the diversified portfolio and the ability to navigate challenges. Conclusion: Abbott Laboratories' ( NYSE:ABT ) recent earnings report might have initially disappointed investors, but a deeper analysis reveals a company that is strategically positioned for growth. With a saucer base forming and a potential buy point at $115.83, savvy investors may see this dip in NYSE:ABT stock as a buying opportunity. Abbott's ability to innovate in the medical devices space, navigate challenges in rapid diagnostics, and shine in electrophysiology suggests that the company is well-poised for sustained success in the dynamic healthcare industry.
NYSE:ABT
by DEXWireNews
ABT Abbott Laboratories Options Ahead of EarningsIf you haven`t bought ABT here: Then analyzing the options chain of ABT Abbott Laboratories prior to the earnings report this week, I would consider purchasing the 108usd strike price in the money Puts with an expiration date of 7/21/2023, for a premium of approximately $2.55. If these options prove to be profitable prior to the earnings release, I would sell at least half of them. Looking forward to read your opinion about it.
NYSE:ABTShort
by TopgOptions
Lagging Ending Diagonal on Abbott. ABTWe are probably at the end of this zigzag in that we are forming what appears to be a lagging diagonal. These tend to be final in a local correction, so it may be that this is the last short I will be putting on this one for a while. We are not in the business of getting every prediction right, no one ever does and that is not the aim of the game. The Fibonacci targets are highlighted in purple with invalidation in red. Confirmation level, where relevant, is a pink dotted, finite line. Fibonacci goals, it is prudent to suggest, are nothing more than mere fractally evident and therefore statistically likely levels that the market will go to. Having said that, the market will always do what it wants and always has a mind of its own. Therefore, none of this is financial advice, so do your own research and rely only on your own analysis. Trading is a true one man sport. Good luck out there and stay safe.
NYSE:ABTShort
by Rykin_Capital
Abbott Labs sinking it down the sink. ABTImmediate targets 112, 109. Invalidation 133. We are not in the business of getting every prediction right, no one ever does and that is not the aim of the game. The Fibonacci targets are highlighted in purple with invalidation in red. Fibonacci goals, it is prudent to suggest, are nothing more than mere fractally evident and therefore statistically likely levels that the market will go to. Having said that, the market will always do what it wants and always has a mind of its own. Therefore, none of this is financial advice, so do your own research and rely only on your own analysis. Trading is a true one man sport. Good luck out there and stay safe
NYSE:ABTShort
by Rykin_Capital
Let's keep an eye on ABT! 👁ABT looks interesting, and it is worth to keep an eye on it! We have a pivot point at 109.52, and this might push ABT to higher levels. It must not break the 107.61, because we have a huge head and shoulders pattern here! In the 4h ABT just hit one of the fibs retracements, and now it is ready to trigger the pivot point at 110.86. If it breaks the first pivot in the 30min, I think ABT might close the gap at 116.51, but we’ll see. We also have a support at 105.37, and we are doing some good movements from here. It seems a fine idea: Tight stop-loss and good upside potential. If you liked this trading idea, remember to click on the “Follow” button to get more trading ideas like this, and if you agree with me, click on the “Agree” button 😉. See you soon, Melissa.
NYSE:ABT
by UnknownUnicorn21312077
4
Flag Pattern on ABT, the way we will trade itToday we will show our analysis and setup we are planning to take on ABT Technical Overview: -The price is inside an ascending channel -Currently is in contact with a key support resistance zone + the ascending trendline -In Technical analysis confluence situations provide interesting places to think in terms of buying or selling pressure Setup development: -We can see an ABC pattern on the confluence zone (support resistance zone + ascending trendline) -IF the price reaches the green line we will consider that as a trigger for our view. We will set stop loss below the structure, break-even on the first fibo extension and take profit on the final fibo extension -IF the price doesn't reach the green line, and keeps falling below the Flag pattern, we will cancel our bullish view. -Risk we are taking on this setup: 1% of our capital Thanks for reading!
NYSE:ABT
by ThinkingAntsOk
2
A Bullish breakout means a 15% upside potential / ABTToday, we will take a look at ABBOTT laboratories. - From a technical perspective, the price is above an ascending channel - Since August 2020, we observed a 150 days consolidation - We can now see an ascending triangle, which is considered a continuation pattern once the flat line is broken. - IF we have a clear breakout, we expect a bullish movement towards 132 - ABBOTT is an extremely bullish stock that has been performing really well (+80% in 2020) - We will consider that the setup is no longer valid if the price goes below 99USD per share
NYSE:ABTLong
by ThinkingAntsOk
2
Potential LONG For Abbott StockIn its latest earnings report, released on 03/31/2020, Abbott reported a quarterly revenue of $7.73 billion and a net profit of $758 million. Abbott Laboratories is expected to post earnings per share (EPS) of $0.32 for the third quarter of 2020. Key Trading Plan: Wait for pull back to the support level of 92.25 before the price eventually rallies up to the Take Profit Target level of 100.29. The upside movement is still strong, hence any SHORT position is kinda risky to take at the moment. ‼️Disclaimer: Please be advised that we are NOT Financial Advisors. We are not responsible for the results of your Forex or CFDs trading. The only person responsible for profits or losses is yourself. You should not consider any market information, educational and analytical material as trading advice that defines your trading actions but purely as educational market material. Please be advised that S.I.D. Capital shall not be liable for any errors in quotes and trading platform software errors. ‼️This Channel and all information is intended for educational purposes only and does not give financial advice. S.I.D. Capital Signals is not a service to provide legal and financial advice; any information provided here is only the personal opinion of the author (not advice or financial advice in any sense, and in the sense of any act, ordinance or law of any country) and must not be used for financial activities.
ALong
by SIDCapital